In vitro activities of DX-619 and four comparator agents against 376 anaerobic bacterial isolates.
The activity of DX-619 was evaluated against 376 anaerobic isolates using the reference CLSI agar dilution method. Overall, 90% of the strains were susceptible to DX-619 at < or =1 microg/ml. It was more active than the other four compounds tested except for meropenem, which showed virtually identical overall activity.
Molitoris
D
D
Medical Service, Greater Los Angeles VAMC, 11301 Wilshire Blvd., Bldg. 304, Rm. E3-237, Los Angeles, CA 90073, USA.
Väisänen
M-L
ML
Bolaños
M
M
Finegold
S M
SM
D000081:Acetamides / Q000494:pharmacology; D019980:Amoxicillin-Potassium Clavulanate Combination / Q000494:pharmacology; D000890:Anti-Infective Agents / Q000494:pharmacology*; D001372:Aza Compounds / Q000494:pharmacology; D001421:Bacteria, Anaerobic / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification; D024841:Fluoroquinolones; D006801:Humans; D066298:In Vitro Techniques; D020128:Inhibitory Concentration 50; D000069349:Linezolid; D000077731:Meropenem; D008826:Microbial Sensitivity Tests; D015394:Molecular Structure; D000077266:Moxifloxacin; D023303:Oxazolidinones / Q000494:pharmacology; D011759:Pyrrolidines / Q000737:chemistry / Q000494:pharmacology*; D011804:Quinolines / Q000494:pharmacology; D015363:Quinolones / Q000737:chemistry / Q000494:pharmacology*; D013845:Thienamycins / Q000494:pharmacology
D000081:Acetamides; D000890:Anti-Infective Agents; D001372:Aza Compounds; C505440:DX 619; D024841:Fluoroquinolones; D023303:Oxazolidinones; D011759:Pyrrolidines; D011804:Quinolines; D015363:Quinolones; D013845:Thienamycins; D019980:Amoxicillin-Potassium Clavulanate Combination; D000077731:Meropenem; D000069349:Linezolid; D000077266:Moxifloxacin